Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.34 |
| ▸ | CHRNA2 | Q15822 | 6/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19679229 | 0.77 | CHRM2 (0.49) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL19684580 | 0.73 | PNMT (0.41) | CHRM3PNMT | |
| SCHEMBL19711568 | 0.70 | PNMT (0.38) | CHRM3RAD52KMT2APNMT | |
| SCHEMBL19678858 | 0.68 | PNMT (0.36) | PNMT | |
| SCHEMBL19684926 | 0.68 | HRH3 (0.41) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL10654976 | 0.66 | CHRM3 (0.82) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL10651499 | 0.65 | CHRM3 (0.84) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL19684653 | 0.64 | HRH3 (0.38) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17664979 | 0.64 | HTR2A (0.46) | HRH3KMT2ATLR7 | |
| SCHEMBL2618741 | 0.63 | CYP2C9 (0.39) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | CHRM3 4771/4885CHRM2 4784/4885CHRM4 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.